-
公开(公告)号：US10376527B2
公开(公告)日：2019-08-13
申请号：US15922170
申请日：2018-03-15
IPC分类号： A61K31/635 , A61K47/14 , A61K47/44 , A61K9/00 , A61K9/08 , A61K47/10 , A61K9/10 , A61K31/415 , A61K47/26 , C07D231/12
摘要： The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
-
公开(公告)号：US10131655B2
公开(公告)日：2018-11-20
申请号：US15269267
申请日：2016-09-19
发明人： Pradip Kumar Sasmal , Chintakunta Vamseekrishna , Vijay Potluri , Ashok Tehim , Yonghua Gai , Hang Zhang
IPC分类号： A61K31/428 , A61K31/404 , A61K31/423 , A61K31/4704 , A61K31/4709 , A61K31/498 , A61K31/538 , A61K31/5415 , C07D417/14 , C07D241/52 , C07D403/12 , C07D413/14 , C07D401/12 , C07D403/14 , C07D413/12 , C07D417/12 , C07D215/227 , C07D263/58 , C07D265/36 , C07D275/06 , C07D277/68 , C07D209/34 , C07D279/16
摘要： The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. wherein R1, R2, R3, R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
-
公开(公告)号：US09968621B2
公开(公告)日：2018-05-15
申请号：US15240577
申请日：2016-08-18
IPC分类号： A61K31/635 , A61K47/24 , A61K9/00 , A61K9/107 , A61K47/44 , A61K31/415 , A61K47/14 , A61K47/10
CPC分类号： A61K31/635 , A61K9/0019 , A61K9/107 , A61K9/1075 , A61K31/415 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/44
摘要： Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.
-
公开(公告)号：US09931469B2
公开(公告)日：2018-04-03
申请号：US14462116
申请日：2014-08-18
发明人： Adam M. Shain , Rajesh Kumar , Anil Namboodiripad
CPC分类号： A61M5/2033 , A61M5/3129 , A61M5/31546 , A61M5/31548 , A61M5/31553 , A61M5/31555 , A61M5/3156 , A61M5/31591 , A61M5/321 , A61M5/50 , A61M2005/206 , A61M2005/2073 , A61M2005/208 , A61M2005/3126 , A61M2205/581 , A61M2205/582 , A61M2205/583
摘要： An auto-injector device for administering a liquid pharmaceutical composition, in which an end-user can select between doses that the device is capable of delivering. The end-user choices that translate into the selected doses can be based on end-user perceived severity of symptoms, end-user weight and other such factors. In some embodiments the auto-injector is configured to administer the one chosen dose only. In other embodiments, the auto-injector can deliver second and subsequent doses up to full dose of the pharmaceutical composition disposed in the injector. The auto-injector can provide visual, audio, and tactile feedback, alone or in combination, to the user to indicate the dose selected, instructions for use, and when the dose has been administered.
-
公开(公告)号：US09655907B2
公开(公告)日：2017-05-23
申请号：US15226684
申请日：2016-08-02
发明人： Udhumansha Ubaidulla , Sateesh Kandavilli , Ajay Sunil Vairale , Jeffrey A. Wayne , Vijendra Nalamothu , Mistry Meghal , Refika Isil Pakunlu
IPC分类号： A61K8/02 , A61K31/573 , A61K9/00 , A61K9/70 , A61K31/56 , A61K31/575 , A61K31/58 , A61K47/10 , A61K47/14 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/44 , A61K47/26 , A61K9/107 , A61K47/22
CPC分类号： A61K31/573 , A61K9/0014 , A61K9/107 , A61K9/7015 , A61K31/56 , A61K31/575 , A61K31/58 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/44 , B05B1/02 , B05B1/30 , B05B11/3045 , B05B15/30
摘要： The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
-
公开(公告)号：US09655885B2
公开(公告)日：2017-05-23
申请号：US14692070
申请日：2015-04-21
发明人： Vishweshwar Peddy , Rajesham Boge , Yogesh S Gattani , Nagoji Shinde , Pradip Kumar Ghosh , Sritharan Seetharaman , Navin Vaya , Vaibhav Sihorkar , Rajashekhar Totad , Krishna Venkatesh , Ganesh Arun Katkar , Snehalatha Movva , Piyush Chudiwal
IPC分类号： C07D277/40 , A61K31/426 , A61K9/14 , A61K9/16
CPC分类号： A61K31/426 , A61K9/146 , A61K9/1635 , C07B2200/13 , C07D277/40
摘要： Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of α form crystal and β form crystal of mirabegron and pharmaceutical composition thereof.
-
公开(公告)号：US09572819B2
公开(公告)日：2017-02-21
申请号：US15167922
申请日：2016-05-27
CPC分类号： A61K31/635 , A61K9/0053 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K31/415 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/44
摘要： The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
摘要翻译： 本发明涉及塞来昔布或其药学上可接受的盐的稳定的口服液体药物组合物。 存在于如本文所述的组合物中的塞来考昔在pH 2.0，温度为37℃±0.5℃，并以50rpm的速度搅拌下在禁食状态模拟胃液（FaSSGF）中经受时不显示任何沉淀 至少60分钟。 它还涉及使用塞来昔布组合物的制备方法和方法。
-
公开(公告)号：US09532996B2
公开(公告)日：2017-01-03
申请号：US14946715
申请日：2015-11-19
CPC分类号： A61K31/65 , A61K9/0053 , A61K9/4816 , A61K9/4866 , A61K9/5078
摘要： Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
摘要翻译： 公开了具有降低的食物效应的强力霉素制剂。 特别公开的是可以每天施用一次并显示降低的食物效果的调制释放制剂。 还公开了治疗诸如红斑痤疮或炎性症状的炎症传导的方法，例如红斑痤疮或寻常型痤疮的丘疹和脓疱。
-
公开(公告)号：US09416152B2
公开(公告)日：2016-08-16
申请号：US14174143
申请日：2014-02-06
发明人： Praveen Cherukupally , Satish Kumar Vujjini , Ganesh Varanasi , Sreenadha Charyulu Kandala , Srinivas Areveli , Satyanarayana Raju Tirumalaraju
IPC分类号： C07H19/12 , C07H17/02 , A61K31/53 , C07D405/04 , C07H13/12
CPC分类号： C07H17/02 , A61K31/53 , C07D405/04 , C07H13/12 , C07H19/12
摘要： The present invention relates to process for the preparation of azacitidine and its crystalline forms.
摘要翻译： 本发明涉及制备阿扎胞苷及其结晶形式的方法。
-
公开(公告)号：US09303027B2
公开(公告)日：2016-04-05
申请号：US13811020
申请日：2011-07-19
申请人： Pradip Kumar Sasmal , Vamsee Krishna Chintakunta , Vijay Potluri , Ish Kumar Khanna , Ashok Tehim , Mahaboobi Jaleel , Thomas Hogberg , Oystein Rist , Lisbeth Elster , Thomas Michael Frimurer , Lars-Ole Gerlach
发明人： Pradip Kumar Sasmal , Vamsee Krishna Chintakunta , Vijay Potluri , Ish Kumar Khanna , Ashok Tehim , Mahaboobi Jaleel , Thomas Hogberg , Oystein Rist , Lisbeth Elster , Thomas Michael Frimurer , Lars-Ole Gerlach
IPC分类号： C07D419/12 , C07D207/09 , C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D207/12 , C07D209/34 , C07D213/76 , C07D215/12 , C07D215/227 , C07D231/56 , C07D249/18 , C07D261/20 , C07D263/56 , C07D263/58 , C07D275/06 , C07D277/30 , C07D279/02 , C07D295/13
CPC分类号： C07D419/12 , C07D207/09 , C07D207/12 , C07D209/34 , C07D213/76 , C07D215/12 , C07D215/227 , C07D231/56 , C07D249/18 , C07D261/20 , C07D263/56 , C07D263/58 , C07D275/06 , C07D277/30 , C07D279/02 , C07D295/13 , C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
摘要翻译： 本发明涉及一系列具有通式（I）的取代的化合物，包括其立体异构体和/或其药学上可接受的盐。 （I）其中A，m，R 1，R 2，R 3，R 4如本文所定义。 本发明还涉及制备这些化合物包括中间体的方法。 本发明的化合物在κ（αKα）阿片受体（KOR）位点是有效的。 因此，本发明的化合物可用作药物，特别是用于治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性疼痛以及相关疾病，特别是周边功能 在CNS。
-
-
-
-
-
-
-
-
-
搜索结果
181 条记录 (耗时 0.049 秒)
